Breaking News Instant updates and real-time market news.

CYTK

Cytokinetics

$9.09

-0.05 (-0.55%)

07:31
10/18/16
10/18
07:31
10/18/16
07:31

Cytokinetics announces first patient enrolled in VIGOR-ALS clinical trial

Cytokinetics announced the first patient has been enrolled in Ventilatory Investigations in Global Open-Label Research in ALS, or VIGOR-ALS, an open-label extension clinical trial designed to assess the long-term safety and tolerability of tirasemtiv, in patients with ALS who have completed their participation in VITALITY-ALS, the Phase 3 clinical trial designed to assess the effects of tirasemtiv versus placebo on slow vital capacity and other measures of respiratory and skeletal muscle function.

  • 20

    Oct

  • 27

    Oct

  • 29

    Nov

CYTK Cytokinetics
$9.09

-0.05 (-0.55%)

11/09/15
ROTH
11/09/15
NO CHANGE
ROTH
Cytokinetics reported positive data, says Roth Capital
Roth Capital says that Cytokinetics' (CYTK) COSMIC-HF met its primary endpoint and all of its secondary endpoints in a study. The firm raised its price target on the stock to $22 from $18. It notes that Amgen (AMGN) is partnering with Cytokinetics on the drug. The firm keeps a Buy rating on Cytokinetics.
12/16/15
PIPR
12/16/15
NO CHANGE
Target $24
PIPR
Overweight
Cytokinetics price target raised to $24 from $17 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised its price target for Cytokinetics to $24 citing greater conviction in the company's pipeline assets ahead of its "busy" 2016. Piper views Cytokinetics as the leader in muscle-biology and reiterates an Overweight rating on the name.
06/21/16
FBRC
06/21/16
NO CHANGE
Target $24
FBRC
Outperform
FBR views Cytokinetics as attractive despite 36% rally
Even with shares up 36% since added to his firm's Alpha Generator list in March, FBR Capital analyst Vernon Bernardino still views shares of Cytokinetics (CYTK) as attractive for an initial investment. The analyst believes partner Amgen (AMGN) will exercise its option and advance omecamtiv mecarbil into Phase III testing in heart failure. Bernardino keeps an Outperform rating on the shares with a $24 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.